Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Investment Type: Venture Capital
Portfolio 2
| Date | Name | Website | Total Raised | Location |
| 22.09.2025 | Avenzo The... | avenzotx.com | $210M | United Sta... |
| 06.09.2025 | Ronovo Sur... | ronovosurgical.com | $161M | China |
Mentions in press and media 13
| Date | Title | Description |
| 03.10.2025 | Avenzo Therapeutics Secures $60 Million Series B to Advance Oncology Breakthroughs | Avenzo Therapeutics secured $60 million in Series B funding. This propels their oncology pipeline. The San Diego biotech now totals $446 million raised. OrbiMed and SR One led the round. New investor Longwood Fund joined. Key existing backe... |
| 23.09.2025 | Avenzo: $60 Million Series B Secured For Developing Oncology Therapies | Avenzo Therapeutics, a biotechnology company focused on developing new cancer treatments, has announced the closing of a $60 million Series B funding round. This latest investment follows a previous $386 million raised through its Series A ... |
| 22.09.2025 | Avenzo Therapeutics Raised $60M in Series B Funding | Avenzo Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing new oncology therapies, raised $60M in Series B funding. The round was led by OrbiMed and SR One, with participation from new investor Longwood Fund,... |
| 06.09.2025 | Ronovo Surgical: $67 Million Series D Raised For Advancing Modular Robotic Surgery | Ronovo Surgical has announced the closing of its Series D financing round, bringing in $67 million in new capital. The round was led by Johnson & Johnson’s corporate venture arm, JJDC, and included participation from Lilly Asia Ventures... |
| 16.05.2025 | Lilly Asia Ventures closes seventh USD fund, rakes in over $547m | Dual-currency biomedical venture firm Lily Asia Ventures (LAV) has closed its seventh USD fund, roping in sovereigns, pensions, endowments, foundations, family offices and funds of funds. |
| 13.02.2025 | New Blood in Innovation: Frank Yin Joins Washington Research Foundation | In the bustling world of innovation, fresh talent can spark a revolution. Frank Yin, Ph.D., is the latest addition to the Washington Research Foundation (WRF) as an investment associate. His mission? To unearth and nurture startup opportuni... |
| 13.02.2025 | Frank Yin joins Washington Research Foundation staff as investment associate | Washington Research Foundation Yin's role will primarily focus on identifying and evaluating startup investment opportunities to advance Washington state innovations for public benefit SEATTLE, Feb. 13, 2025 /PRNewswire-PRWeb/ -- Frank Yin,... |
| 13.01.2025 | Timberlyne: $180 Million (Series A) Raised To Develop Novel Therapies For Autoimmune Disorders | Timberlyne Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel therapies for autoimmune disorders, announced the closing of a $180 million Series A financing to advance CM313, a potentially best-in-c... |
| 10.05.2021 | Alebund Pharmaceuticals Raises $60 million in Series B Financing Round to Accelerate Its Development of Innovative Drugs and Total Solutions for the Treatment of Renal Diseases | SHANGHAI, May 10, 2021 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chroni... |
| 26.07.2016 | Gates Foundation leads $14M funding round for Just Biotherapeutics to battle infectious diseases | Just Biotherapeutics CEO and Founding Partner Jim Thomas Seattle-based Just Biotherapeutics said Monday it closed a $14 million funding round led by the Bill & Melinda Gates Foundation. A group of former Amgen scientists founded Just in... |
Show more